REQUEST A DEMO
Total
USD $0.00
Search more companies

Uropharma Sp. z o.o. (Poland)

Main Activities: Pharmaceutical Preparation Manufacturing
Secondary Activities: Pharmaceutical and Medicine Manufacturing | Merchant Wholesalers, Durable Goods | Retail Trade
Full name: Uropharma Sp. z o.o. Profile Updated: May 19, 2024
Buy our report for this company USD 19.99 Most recent financial data: 2025 Available in: English & Polish Download a sample report

Uropharma Sp. z o.o. is based in Poland. The head office is in Warsaw. It operates in the Pharmaceutical Preparation Manufacturing sector. It was first established on December 09, 2020. In its most recent financial highlights, the company reported a net sales revenue increase of 139.22% in 2025. Its total assets grew by 227.48% over the same period. The net profit margin of Uropharma Sp. z o.o. increased by 2.06% in 2025.

Headquarters
Ul. Waclawa Wojtyszki 8F
Warsaw; Mazowieckie; Postal Code: 04-785

Contact Details: Purchase the Uropharma Sp. z o.o. report to view the information.

Basic Information
Registered Capital:
Purchase the Uropharma Sp. z o.o. report to view the information.
Financial Auditors:
Purchase the Uropharma Sp. z o.o. report to view the information.
Incorporation Date:
December 09, 2020
Key Executives
Purchase this report to view the information.
President
Ownership Details
Purchase this report to view the information.
51%
Purchase this report to view the information.
49%
Company Performance
Financial values in the chart are available after Uropharma Sp. z o.o. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency PLN. Absolute financial data is included in the purchased report.
Net sales revenue
139.22%
Total Operating Revenue
139.22%
Operating Profit
206.56%
Net Profit/Loss for the Period
395%
Total Assets
227.48%
Total Equity
388.64%
Operating Profit Margin
0.97%
Net Profit Margin
2.06%
Return on Equity (ROE)
0.32%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?